Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies.
James Waldron
Jun 13, 2025 8:00am
Merck's oral PCSK9 inhibitor leader reduces cholesterol in ph. 3
Jun 9, 2025 9:00am
Merck made $3B offer for MoonLake—and could revive interest: FT
Jun 3, 2025 9:25am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
Merck takes middle dose of ROR ADC forward into phase 3
May 30, 2025 9:51am
Daiichi, Merck pull HER3-DXd filing at FDA
May 29, 2025 9:40am
